Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADC3680 in Inadequately-Controlled Asthma
NCT01730027Phase 2Completed
- Sponsor
- Pulmagen Therapeutics
- Start
- Apr 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of GB001 in asthma (3 arms), sponsored by Pulmagen Therapeutics. Primary endpoint: Forced Expiratory Volume in 1 Second at 10 weeks. Started Apr 2013; status: completed.
02
Drugs
GB001
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01730027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730027.